The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...

Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...

Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Monday, January 13, 2025, 13:00 Hrs [IST] ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

H.C. Wainwright analyst Andres Maldonado keeps a Buy rating on CG Oncology (CGON) with a $75 price target after Pfizer (PFE) announced positive ...

Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...